Horizon CombinatoRx to Profile Oncology Asset for Pharma Firm | GenomeWeb

NEW YORK(GenomeWeb) – Horizon Discovery today said that its CombinatoRx division has inked a contract with an unnamed "top 10" pharmaceutical firm to profile a lead oncology asset. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.